Onglyza and Weight loss - a phase IV clinical study of FDA data

Summary:

Weight loss is reported as a side effect among people who take Onglyza (saxagliptin hydrochloride), especially for people who are male, 50-59 old, also take Metformin, and have High blood cholesterol.

The phase IV clinical study analyzes which people have Weight loss when taking Onglyza. It is created by eHealthMe based on reports of 8,520 people who have side effects when taking Onglyza from the FDA, and is updated regularly.

What is Onglyza?

Onglyza has active ingredients of saxagliptin hydrochloride. It is often used in diabetes. eHealthMe is studying from 8,638 Onglyza users. Check the latest studies of Onglyza.

What is Weight loss?

Weight loss is found to be associated with 1,458 drugs and 2,291 conditions by eHealthMe. Check the latest studies of Weight loss.

On Jul, 04, 2026

8,520 people reported to have side effects when taking Onglyza.
Among them, 17 people (0.2%) have Weight loss.

Among these 17 people:

What is the gender of people who have Weight loss when taking Onglyza? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Weight loss when taking Onglyza? *

What are other drugs people take besides Onglyza? *

Metformin: 4 people, 23.53%
Adalat: 3 people, 17.65%
Aldactone: 3 people, 17.65%
Insulin: 3 people, 17.65%
Diovan Hct: 3 people, 17.65%
Dilaudid: 3 people, 17.65%
Pantoprazole: 3 people, 17.65%
Colchicine: 2 people, 11.76%
Levemir: 2 people, 11.76%
Esomeprazole Magnesium: 2 people, 11.76%

What are other side effects people have besides Weight loss? *

Gout (uric acid crystals building up in the body): 4 people, 23.53%
High Blood Pressure: 4 people, 23.53%
Poor Peripheral Circulation: 3 people, 17.65%
Hyperlipidaemia (presence of excess lipids in the blood): 3 people, 17.65%
Memory Loss: 3 people, 17.65%
Stress And Anxiety: 3 people, 17.65%
Pneumonia: 3 people, 17.65%
Speech Disorder: 3 people, 17.65%
Carotid Artery Stenosis (narrowing of carotid artery): 3 people, 17.65%
Hepatic Steatosis (fatty liver disease): 3 people, 17.65%

What are the existing conditions these people have? *

High Blood Cholesterol: 4 people, 23.53%
High Blood Pressure: 3 people, 17.65%
Pain: 3 people, 17.65%
Gastric Disorder (disease of stomach): 3 people, 17.65%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 2 people, 11.76%
Essential Hypertension (primary hypertension): 2 people, 11.76%
Fluid Retention (an abnormal accumulation of fluid in the blood): 2 people, 11.76%
Hyperlipidaemia (presence of excess lipids in the blood): 2 people, 11.76%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 2 people, 11.76%
Depression: 1 person, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Onglyza and have Weight loss?

- Check whether Weight loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Onglyza:

Onglyza (8,638 reports)

Weight loss treatments and more:

Weight loss (62,430 reports)

Browse all side effects of Onglyza:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weight loss:

Weight loss (1,458 drugs)

Browse all the conditions that are associated with Weight loss:

Weight loss (2,291 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on saxagliptin hydrochloride (the active ingredients of Onglyza) and Onglyza (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.